Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles

Oncotarget

Volumn 7, Issue 16, 2016, Pages 22566-22578

  Koppers Lalic, Danijela ^a,b   Hackenberg, Michael ^c   De Menezes, Renee ^a   Misovic, Branislav ^d   Wachalska, Magda ^a   Geldof, Albert ^e   Zini, Nicoletta ^e,f   De Reijke, Theo ^g   Wurdinger, Thomas ^a,h   Vis, Andre ^a   Van Moorselaar, Jeroen ^a   Pegtel, Michiel ^a   Bijnsdorp, Irene ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Exbiome BV   (Netherlands)

^c UNIVERSITY OF GRANADA   (Spain)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CNR   (Italy)

^f RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Extracellular vesicles; IsomiRs; Liquid biopsy; MiRNA; RNA sequencing

Indexed keywords

MICRORNA; MICRORNA 204; MICRORNA 21; MICRORNA 375; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ISOPROTEIN; TUMOR MARKER;

3' UNTRANSLATED REGION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EXOSOME; HUMAN; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; PATHOGENESIS; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDATION STUDY; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PROSTATE TUMOR; URINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOMARKERS, TUMOR; EXTRACELLULAR VESICLES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84965006909     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8124     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014 CA. Cancer J. Clin. 2014; 64:9-29.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N. EAU guidelines on prostate cancer. part 1:screening, diagnosis, and local treatment with curative intent-update 2013. Eur. Urol. 2014; 65:124-37.
3. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, RatliffTL, Kavoussi LR, Dalkin BL. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer:results of a multicenter clinical trial of 6, 630 men. J Urol. 1994; 151:1283-1290.
4. Oesterling JE. Prostate specific antigen:a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991; 145:907-923.
5. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, Rimmer J, Sturgeon C, White P, Allen NE. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis. Eur. Urol. 2005; 48:386-398.
6. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schröder FH, van Leenders GJLH. False-negative prostate needle biopsies:frequency, histopathologic features, and follow-up. Am. J. Surg. Pathol. 2010; 34:35-43.
7. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, Rosario DJ, Scattoni V, Lotan Y. Systematic review of complications of prostate biopsy. Eur. Urol. 2013; 64:876-892.
8. Bijnsdorp I V, Geldof AA, Lavaei M, Piersma SR, van Moorselaar RJA, Jimenez CR. Exosomal ITGA3 interferes with non-cancerous prostate cell functions and is increased in urine exosomes of metastatic prostate cancer patients. J. Extracell. vesicles. 2013; 2:1-10.
9. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. Prostate cancer-derived urine exosomes:a novel approach to biomarkers for prostate cancer. Br. J. Cancer. 2009; 100:1603-1607.
10. Dijkstra S, Birker IL, Smit FP, Leyten GHJM, De Reijke TM, Van Oort IM, Mulders PFA, Jannink SA, Schalken JA. Prostate cancer biomarker profiles in urinary sediments and exosomes. J. Urol. 2014; 191:1132-1138.
11. Larne O, Martens-Uzunova E, Hagman Z, Edsjö A, Lippolis G, Den Berg MSV Van, Bjartell A, Jenster G, Ceder Y. MiQ-A novel microRNA based diagnostic and prognostic tool for prostate cancer. Int. J. Cancer. 2013; 132:2867-2875.
12. Morin R, O'Connor M, Griffith M, Kuchenbauer F, Delaney A, Prabhu A-L, Zhao Y, McDonald H, Zeng T, Hirst M, Eaves C, Marra M. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008; 18:610-621.
13. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, Li X, Berry DL, Kallakury BVS et al. MicroRNA Profiling in Prostate Cancer-The Diagnostic Potential of Urinary miR-205 and miR-214. PLoS One. 2013; 8.
14. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar CM, Nitadori-Hoshino A, Hoffman C, Badal K et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012; 18:883-891.
15. Ayub S; KDAT. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer. Cancer Genet. 2015; 208:289-302.
16. Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, Kuslich C, Visakorpi T, Hamdy FC. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer. 2012; 106:768-74.
17. Haldrup C, Kosaka N, Ochiya T, Borre M, Høyer S, Orntoft TF, Sorensen KD. Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv. Transl. Res. 2013; 4:19-30.
18. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, Yang J. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012; 72:1443-1452.
19. Neilsen CT, Goodall GJ, Bracken CP. IsomiRs-The overlooked repertoire in the dynamic microRNAome. Trends Genet. 2012; 28:544-549.
20. Cloonan N, Wani S, Xu Q, Gu J, Lea K, Heater S, Barbacioru C, Steptoe AL, Martin HC, Nourbakhsh E, Krishnan K, Gardiner B, Wang X et al. MicroRNAs and their isomiRs function cooperatively to target common biological pathways. Genome Biol. 2011; 12:R126.
21. Katoh T, Sakaguchi Y, Miyauchi K, Suzuki T, Suzuki T, Kashiwabara SI, Baba T. Selective stabilization of mammalian microRNAs by 3' adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. Genes Dev. 2009; 23:433-438.
22. D'Ambrogio A, Gu W, Udagawa T, Mello CC, Richter JD. Specific miRNA Stabilization by Gld2-Catalyzed Monoadenylation. Cell Rep. 2012; 2:1537-1545.
23. Telonis AG, Loher P, Jing Y, Londin E, Rigoutsos I. Beyond the one-locus-one-miRNA paradigm:microRNA isoforms enable deeper insights into breast cancer heterogeneity. 2015:43:1-18.
24. Koppers-Lalic D, Hackenberg M, Bijnsdorp IV, van Eijndhoven MA, Sadek P, Sie D, Zini N, Middeldorp JM, Ylstra B, de Menezes RX, Würdinger T, Meijer GA, Pegtel DM. Cell Rep. 2014;8:1649-58.
25. Bellingham SA, Coleman BM, Hill AF. Small RNA deep sequencing reveals a distinct miRNA signature released in exosomes from prion-infected neuronal cells. Nucleic Acids Res. 2012; 40:10937-10949.
26. Hessvik NP, Phuyal S, Brech A, Sandvig K, Llorente A. Profiling of microRNAs in exosomes released from PC-3 prostate cancer cells. Biochim. Biophys. Acta-Gene Regul. Mech. 2012; 1819:1154-1163.
27. Leyten GHJM, Hessels D, Smit F, Jannink S, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PFA, et al. Identification of a candidate gene panel for the early diagnosis of prostate cancer. Clin. Cancer Res. 2015; 3:3061-3071.
28. Cha DJ, Franklin JL, Dou Y, Liu Q, Higginbotham JN, Demory Beckler M, Weaver AM, Vickers K, Prasad N, Levy S, Zhang B, Coffey RJ, Patton JG. KRAS-dependent sorting of miRNA to exosomes. Elife. 2015; 4:1-22.
29. Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi S. Exosome and Exosomal MicroRNA:Trafficking, Sorting, and Function. Genomics. Proteomics Bioinformatics. 2015; 13:17-24.
30. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer:biomarkers, functions and therapy. Trends Mol. Med. 2014; 20:460-469.
31. Boing AN, Pol E Van Der, Grootemaat AE, Coumans FA., Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles from plasma by size-exclusion chromatography. J Extracell Vesicles. 2014 8; 3.
32. Van Gils MPMQ, Hessels D, Van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, Witjes JA, Cornel EB, Karthaus HFM, Smits GAHJ, Dijkman GA, Mulders PFA, Schalken JA. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin. Cancer Res. 2007; 13:939-943.
33. Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, Oort IM Van, Mulders PFA, Schalken JA. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clin. Chem Lab Med. 2016;54:483-92.
34. Hessels D, Klein Gunnewiek JMT, Van Oort I, Karthaus HFM, Van Leenders GJL, Van Balken B, Kiemeney L a., Witjes JA, Schalken J A., Culig Z. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003; 44:8-16.
35. Lakings DB, Waalkes TP, Borek E, Gehrke CW, Mrochek JE, Longmore J, Adamson RH. Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen induced hepatoma and normal monkey livers. Cancer Res. 1977; 37:285-292.
36. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJLH, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012; 31:978-991.
37. Honda S, Loher P, Shigematsu M, Palazzo JP, Suzuki R, Imoto I, Rigoutsos I, Kirino Y. Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc. Natl. Acad. Sci. U. S. A. 2015; 112:E3816-25.
38. Lee LW, Zhang S, Etheridge A, Ma L, Martin D, Galas D, Wang K. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 2010; 16:2170-2180.
39. Sapre N, Hong MKH, Macintyre G, Lewis H, Kowalczyk A, Costello AJ, Corcoran NM, Hovens CM. Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One. 2014; 9:e91729.
40. Honda S, Kirino Y. Dumbbell-PCR:a method to quantify specific small RNA variants with a single nucleotide resolution at terminal sequences. Nucleic Acids Res. 2015; 43:e77.
41. Boele J, Persson H, Shin JW, Ishizu Y, Newie IS, Sokilde R, Hawkins SM, Coarfa C, Ikeda K, Takayama K-I., Horie-Inoue K, Ando Y, Burroughs A. M et al. PAPD5-mediated 3' adenylation and subsequent degradation of miR-21 is disrupted in proliferative disease. Proc. Natl. Acad. Sci. 2014:2-7.
42. Donovan MJ, Noerholm M, Bentink S, Belzer S, Skog J, O'Neill V, Cochran JS, Brown GA. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result. Prostate Cancer Prostatic Dis. 2015;18:370-5
43. D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, Wein A CC. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys. 1997; 37:1053-2008.
44. Hackenberg M, Rodríguez-Ezpeleta N, Aransay AM. MiRanalyzer:An update on the detection and analysis of microRNAs in high-throughput sequencing experiments. Nucleic Acids Res. 2011; 39.
45. Barturen G, Rueda A, Hamberg M, Alganza A, Lebron R, Kotsyfakis M, Shi B-J, Koppers-Lalic D, Hackenberg M. sRNAbench:profiling of small RNAs and its sequence variants in single or multi-species high-throughput experiments. Methods Next Gener. Seq. 2014; 1:21-31.
46. Robinson MD, McCarthy DJ, Smyth GK. edgeR:a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26:139-140.